Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2021 May 24;11:10734. doi: 10.1038/s41598-021-90220-8

The roles and prognostic significance of ABI1-TSV-11 expression in patients with left-sided colorectal cancer

Yu Zhang 1,2,#, Zhaohui Zhong 3,#, Mei Li 1, Jingyi Chen 1,2, Tingru Lin 1,2, Jie Sun 1, Di Wang 1, Qing Mu 1, Huiting Su 1, Na Wu 1, Aiyu Liu 1, Yimeng Yu 1, Menglei Zhang 4, Yulan Liu 2, Jingzhu Guo 5,✉, Weidong Yu 1,✉
PMCID: PMC8144562  PMID: 34031495

Abstract

Abnormally expressed and/or phosphorylated Abelson interactor 1 (ABI1) participates in the metastasis and progression of colorectal cancer (CRC). ABI1 presents as at least 12 transcript variants (TSVs) by mRNA alternative splicing, but it is unknown which of them is involved in CRC metastasis and prognosis. Here, we firstly identified ABI1-TSV-11 as a key TSV affecting the metastasis and prognosis of left-sided colorectal cancer (LsCC) and its elevated expression is related to lymph node metastasis and shorter overall survival (OS) in LsCC by analyzing data from The Cancer Genome Atlas and TSVdb. Secondly, ABI1-TSV-11 overexpression promoted LoVo and SW480 cells adhesion and migration in vitro, and accelerated LoVo and SW480 cells lung metastasis in vivo. Finally, mechanism investigations revealed that ABI1-isoform-11 interacted with epidermal growth factor receptor pathway substrate 8 (ESP8) and regulated actin dynamics to affect LoVo and SW480 cells biological behaviors. Taken together, our data demonstrated that ABI1-TSV-11 plays an oncogenic role in LsCC, it is an independent risk factor of prognosis and may be a potential molecular marker and therapeutic target in LsCC.

Subject terms: Transcriptomics, Cancer

Introduction

Colorectal cancer (CRC) accounts for the third morbidity and the second mortality in cancer-related diseases in the worldwide1. Metastasis is still the leading cause of CRC death though advances in strategies for early diagnosis and treatment2 and it is a dynamic biological process that includes separation from the primary site, degradation of extracellular matrix, invasion into blood and lymphatic vessels, migration and movement in vessels, and distant colonization and neovascularization3–5. One or more of the above processes is blocked, the process of tumor metastasis would be inhibited. Left-sided colorectal cancer (LsCC) and right-sided colorectal cancer (RsCC) have significant differences in epidemiological characteristics, molecular biological characteristics, metastatic behavior, and disease outcome6. For example, Chromosomal instability is more common in LsCC patients, and the prognosis of LsCC patients in TNM II stage is worse than that of RsCC6,7. Therefore, stratified analysis based on LsCC and RsCC subgroups may benefit to personalized treatment and mortality reduction.

Abelson interactor 1 (ABI1) is an important adaptor protein and its abnormal expression and/or phosphorylation are involved in regulating the behaviors of tumor cells, such as proliferation, adhesion, migration and invasion, and thereby affecting the metastasis and progression of various malignant tumors, including CRC8–13. ABI1 regulates tumor cell proliferation by binding to c-Abl14, v-Abl15, EPS816 and the p85 subunits of PI3K17. It also regulates cell–cell adhesion, cell–extracellular matrix adhesion, cell extension, migration and invasion of tumor cells by forming multi-protein complexes with WAVE218–20, PI3K17,21, EPS811,22,23 and N-WASP24. ABI1 has been reported to serve as an oncogene in CRC8,25–27, leukemia9,28, breast cancer10,29,30, ovarian cancer11,31 and hepatocellular carcinoma12,32. There is also evidence suggesting that it may serve as a tumor suppressor gene in prostate cancer18,33,34, gastric cancer35,36 and neuroblastoma37. Recent studies have shown that ABI1 is highly expressed25,26 and hypophosphorylated38 in CRC tissues. Especially, ABI1 is located at the invasive fronts of tumor tissues25 and the sites of degradation of extracellular matrix8. There are correlations of ABI1 expression with infiltration depth and degree of differentiation of CRC tumor, and CRC patients with high ABI1 expression have a lower 5-year survival rate and poorer prognosis25. In addition, ABI1 pY435 is necessary for CRC cells to form lamellipodium-like cellular protrusions8,27.

Alternative splicing (AS), one of the post-transcriptional regulatory mechanisms, is the main factor accounting for proteomic diversity39. And differential transcript variants (TSVs) expression of some genes is associated with the metastasis of CRC40,41. ABI1 is a multi-exon gene and has at least 12 TSVs42. Different ABI1-TSVs often play synergistic or antagonistic roles in the same pathophysiological events21,43. However, the role of ABI1-TSVs in the metastasis of CRC has not yet been investigated.

The Cancer Genome Atlas (TCGA) integrates the sequencing data of 33 types of cancer and normal samples, as well as detailed follow-up information44 and TSVdb (http://tsvdb.com) is an open visualization database to study the differential expression of TSVs in various tumors45. In this study, we set out to investigate the roles of ABI1-TSVs in regulating tumor metastasis and progression. We found a key ABI1-TSV, ABI1-TSV-11, that associates with lymph node metastasis and short overall survival (OS) and thus serves as an independent risk factor for LsCC. We proved that ABI1-TSV-11 overexpression promoted the adhesion and migration of LoVo and SW480 cells and the invasion of LoVo cells in vitro, and accelerated the lung metastasis of LoVo and SW480 cells in vivo. We also demonstrated that ABI1-isoform-11 (the ABI1-TSV-11-encoded protein isoform) interacts with EPS8 to regulate the adhesion, migration, and invasion of LoVo and SW480 cells by affecting actin dynamics.

Results

Elevated expression of ABI1-TSV-11 correlates with lymph node metastasis and predicts poor prognosis in patients with LsCC

To determine the clinical significance and underlying role of ABI1-TSVs in CRC and its subgroups (LsCC and RsCC), we first analyzed the correlations between the clinicopathological information (sex, age, ethnicity, TNM stage, etc.) and survival time (OS; disease-free survival, DFS) by Kaplan–Meier analysis and chi-squared test to evaluate the reliability and representativeness of data. As shown in Table 1, TNM stage was closely related to survival time (OS, DFS) and the selected cases are representative of the typical clinicopathological and prognostic characteristics of CRC patients.

Table 1.

The correlation between clinicopathological characteristics and OS/ DFS in CRC, LsCC and RsCC patients from TCGA database.

Characteristics OS DFS
CRC LsCC RsCC CRC LsCC RsCC
χ2 P χ2 P χ2 P χ2 P χ2 P χ2 P
Sex 0.904 0.342 0.083 0.774 1.476 0.224 2.545 0.111 0.918 0.338 0.507 0.477
Age 10.675 0.001 7.283 0.007 2.125 0.145 0.055 0.815 0.018 0.893 0.280 0.597
Race 0.186 0.911 0.286 0.867 0.180 0.914 0.823 0.663 0.624 0.732 0.771 0.680
Clinical stage 19.041 0.000 10.624 0.001 10.975 0.001 20.781 0.000 9.937 0.002 11.082 0.001
Infiltration depth 2.804 0.094 0.116 0.734 5.518 0.019 9.111 0.003 1.849 0.174 6.981 0.008
Lymph-node metastasis 17.505 0.000 9.258 0.010 12.840 0.002 23.180 0.000 11.658 0.003 24.627 0.000
Distant metastasis 19.612 0.000 2.032 0.154 24.049 0.000 24.286 0.000 5.938 0.015 15.097 0.000
KRAS mutation 0.732 0.392 1.001 0.317 1.582 0.208 0.963 0.326 2.253 0.133 0.039 0.844
Open in a new tab

CRC colorectal cancer, DFS disease-free survival, LsCC left-sided colorectal cancer, OS over-all survival, RsCC right-sided colorectal cancer.

Next, we found that increased ABI1-TSV-11 (Abelson interactor 1 transcript variant 11) expression correlated with lymph node metastasis (P = 0.050, Table 2) in LsCC, and there was no correlation between ABI1-TSV-11 overexpression and KRAS mutation. Notably, Kaplan–Meier analysis showed that, in the CRC group and LsCC group, the 10-year OS rates (32.1% and 44.3%, respectively) in patients with high ABI1-TSV-11 expression were significantly lower than in those with low ABI1-TSV-11 expression (53.8% and 51.5%, respectively; P = 0.020 and P = 0.004; Fig. 1a,b). There were no statistically significant differences in 10-year DFS rates observed between patients with high expression and low expression of ABI1-TSV-11(Fig. 1d,e). In the RsCC group, while patients with high ABI1-TSV-11 expression showed 10-year OS and DFS rates lower than those with low ABI1-TSV-11 expression, the differences were not statistically significant (Fig. 1c,f).The results of Multivariate Cox proportional hazards models showed that ABI1-TSV-11 could serve as an independent risk factor in LsCC [hazard ratio (HR) = 3.060, P = 0.008; Table 3], but not an independent risk factor in CRC (Table 4). Taken together, these results indicate that ABI1-TSV-11 is a specific prognostic risk factor and may serve as a therapeutic target for patients with LsCC.

Table 2.

The correlation between ABI1-TSV-11 expression and clinicopathological characteristics of CRC, LsCC and RsCC patients from TCGA.

Characteristics CRC LsCC RsCC
n Low/high χ2 P n Low/high χ2 P n Low/high χ2 P
Sex 339 3.027 0.082 168 2.914 0.088 154 1.765 0.184
Male 98/88 41/43 48/42
Female 95/58 52/32 41/23
Age 339 1.039 0.308 168 5.154 0.023 154 0.499 0.480
< 65 102/69 62/37 36/30
≥ 65 91/77 31/38 53/35
Race 309 0.328 0.849 149 2.741 0.254 143 2.673 0.263
Asian 5/5 3/0 2/5
Black 34/23 12/7 22/14
White 140/102 70/57 59/41
Clinical stage 323 0.207 0.649 160 0.243 0.622 146 0.027 0.869
I + II 100/72 45/34 49/36
III + IV 84/67 43/38 36/25
Infiltration depth 337 0.985 0.321 167 1.374 0.241 154 0.001 0.977
T1 + T2 39/23 19/10 19/14
T3 + T4 154/12 74/64 70/51
Lymph-node metastasis 337 2.550 0.279 166 5.985 0.050 154 0.073 0.964
N0 107/78 47/36 54/39
N1 55/35 36/21 15/12
N2 30/32 9/17 20/14
Distant metastasis 275 0.025 0.874 141 0.132 0.717 121 0.330 0.566
M0 129/99 65/51 59/44
M1 26/21 15/10 9/9
KRAS mutation 55 0.009 0.925 28 0.084a 21 0.080b
No 18/9 9/6 8/2
Yes 19/9 12/1 4/7
Open in a new tab

a–b fisher exact test.All others are Chi-square tests.

CRC colorectal cancer, DFS disease-free survival, LsCC left-sided colorectal cancer, OS over-all survival, RsCC right-sided colorectal cancer.

Figure 1.

Figure 1

Open in a new tab

Elevated expression of ABI1-TSV-11 is related to shorter overall survival of CRC and LsCC patients. (a)–(c) Kaplan–Meier analysis of the correlation between ABI1-TSV-11 expression and overall survival in colorectal cancer (CRC, a, n = 339, P = 0.020), left-sided colorectal cancer (LsCC, b, n = 168, P = 0.004), and right-sided colorectal cancer (RsCC, c, n = 154, P = 0.673). (d)–(f) Kaplan–Meier analysis of the correlation between ABI1-TSV-11 and disease-free survival in CRC (d, n = 339, P = 0.140), LsCC (e, n = 168, P = 0.383), and RsCC (f, n = 154, P = 0.249); log-rank test, P < 0.05, significant.

Table 3.

Univariate and multivariate analysis of factors associated with overall survival in 168 LsCC patients.

Variables Univariate analysis Multivariate analysis
HR 95%CI P HR 95%CI P
T (T1-T2/T3-T4) 1.184 0.448–3.130 0.734
N (N0, N1, N2) 1.953 1.239–3.079 0.004
M (M0, M1) 1.927 0.770–4.826 0.161
Clinical stage (I-II/ III-IV) 3.701 1.601–8.555 0.002 6.384 2.590–15.734 0.000
ABI1-TSV-11 2.787 1.351–5.751 0.006 3.060 1.346–6.955 0.008
Age 2.632 1.268–5.465 0.009 4.072 1.768–9.370 0.001
Open in a new tab

Table 4.

Univariate and multivariate analysis of factors associated with survival in 339 total CRC patients.

Variables Univariate analysis Multivariate analysis
HR (Hazard Ratio) 95%CI (Confidence interval) P HR 95%CI P
T (T1-T2/T3-T4) 1.854 0.890–3.863 0.099
N (N0, N1, N2) 1.825 1.399–2.381 0.000
M (M0, M1) 3.230 1.866–5.591 0.000
Clinical stage (I-II/III-IV) 2.870 1.750–4.708 0.000 2.687 1.608–4.490 0.000
ABI1-TSV-11 1.690 1.082–2.640 0.021
Age 2.187 1.351–3.539 0.001 3.248 1.973–5.347 0.000
Open in a new tab

The construction of stable cell lines overexpressing ABI1-TSV-11

To determine the biological function of ABI1-TSV-11 in LsCC, we first analyzed the expression of ABI1-TSV-11 in a normal colorectal epithelial cell line (CRL-1541) and three CRC cell lines (LoVo, SW480, SW620) by next-generation sequencing (Fig. 2a), and LoVo and SW480 cell lines, which originate from LsCC and have low endogenous ABI1-TSV-11 expression and different invasiveness, were then selected, to construct the stable ABI1-TSV-11 overexpressed cell models. As shown in Fig. 2b–d, quantitative real-time PCR (qRT-PCR) and western blotting confirmed the successful construction of stable cell lines at the mRNA and protein levels. As shown in Fig. S1, EPS8 Knockdown were confirmed at the mRNA by qRT-PCR.

Figure 2.

Figure 2

Open in a new tab

The construction of ABI1-TSV-11-overexpressing LoVo and SW480 cell models in vitro. (a) Relative expression levels of endogenous ABI1-TSV-11 in the normal colorectal cell line (CRL-1541) and CRC cell lines (LoVo, SW480, SW620) (RNA sequencing). (b) and (c) fluorescence images and quantitative real-time PCR analysis using ABI1 universal primers of in LoVo-ABI1-TSV-11 and SW480-ABI1-TSV-11 cell lines after lentivirus infection and puromycin selection, as well as their controls. (d) Western blotting analysis of ABI1-TSV-11 in LoVo-ABI1-TSV-11 and SW480-ABI1-TSV-11 cell lines and their corresponding controls using HA antibody.

ABI1-TSV-11 overexpression promotes LoVo and SW480 adhesion, migration, and invasion in vitro

To investigate the effects of ABI1-TSV-11 overexpression on cell adhesion and motility, we performed adhesion, Transwell migration, and invasion assays in vitro. For the adhesion, we firstly compared the adhesion ability of LoVo and SW480 cells under routine culture conditions (Fig. 3a) and found that the adhesion ability of LoVo cells was significantly weaker than that of SW480 cells on PBS- or 0.02% BSA-coated plates (P < 0.05). Next, we compared the adhesion ability of the two types of cell on fibronectin-, gelatin-, and collagen I-coated culture plates, and found that although their adhesion ability was significantly enhanced compared with that of PBS and 0.02% BSA (P < 0.05), their responses to stimulation with fibronectin, gelatin, and collagen I were not significantly different (Fig. 3a,b).

Figure 3.

Figure 3

Open in a new tab

ABI1-TSV-11 overexpression enhances the cell–fibronectin adhesion of LoVo and SW480 cells in vitro. (a) Comparison of the adhesion ability between LoVo and SW480 cells under different coating conditions. (b) Changes in the adhesion ability of LoVo and SW480 cells under different coating conditions. (c) ABI1-TSV-11 overexpression enhanced the cell–fibronectin adhesion of LoVo cells. (d) ABI1-TSV-11 overexpression enhanced the cell–fibronectin adhesion of SW480 cells (one-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001, ns, not significant).

As shown in Fig. 3c,d, ABI1-TSV-11 overexpression did not affect the adhesion of LoVo and SW480 cells on PBS-, 0.02% BSA-, collagen I-, and gelatin-coated plates. However, ABI1-TSV-11 overexpression significantly enhanced the adhesion of LoVo and SW480 cells on fibronectin-coated plates (Fig. 3c). On the fibronectin-coated culture plates, the LoVo and SW480 cells overexpressing ABI1-TSV-11 showed different responses to fibronectin. While the overexpression of ABI1-TSV-11 inhibited LoVo cell adhesion to fibronectin, it promoted that of SW480 cells (Fig. 3c,d). To address why ABI1-TSV-11 over-expression in the LoVo and SW480 cells induces distinct responses on adhesion to fibronectin, we analyzed the mRNA expression profile of integrins using RNA-seq data of LoVo and SW480 cells, and found that the differential expression of these integrins, especially ITGB1, in SW480 and LoVo cells induces distinct responses on adhesion to fibronectin (Fig. S2).

For migration and invasion, we found that ABI1-TSV-11 overexpression increased the migration and invasion of LoVo-ABI1-TSV-11 by 4.57- and 5.96-fold, respectively, compared with those of their parental control cells (both P < 0.05; Fig. 4g,o). ABI1-TSV-11 overexpression increased the migration of SW480-ABI1-TSV-11 cells by 17% (Fig. 4h, P < 0.05), but was not sufficient to stimulate the invasion of SW480-ABI1-TSV-11 cells (Fig. 4p, P > 0.05). To address why ABI1-TSV-11 over-expression in the LoVo and SW480 cells induces distinct responses on Matrigel invasion, we analysis the mRNA expression of MMP2 and MMP9, and found that ABI1-TSV-11 overexpression in LoVo cells could significantly increase the mRNA expression of MMP2 and MMP9, but not change the mRNA expression of them in SW480 cells. That means that it is these differences induces distinct responses on Matrigel invasion (Fig. S3).

Figure 4.

Figure 4

Open in a new tab

ABI1-TSV-11 overexpression enhances LoVo and SW480 cell migration and LoVo cell invasion in vitro. (a)–(c) Microscopic fields of LoVo-ABI1-TSV-11 cells and their control cells after migrating for 4 h. (d)–(f) Microscopic fields of SW480-ABI1-TSV-11 cells and their control cells after migrating for 8 h. (j)–(k) Microscopic fields of LoVo-ABI1-TSV-11 cells and their control cells after invading for 8 h. (l)–(n) Microscopic fields of SW480-ABI1-TSV-11 cells and their control cells after invading for 14 h. (g)–(h) Quantitative analysis of the effect of ABI1-TSV-11 overexpression on LoVo and SW480 cells’ migratory ability. (o)–(p) Quantitative analysis of the effect of ABI1-TSV-11 on LoVo and SW480 cells’ invasive ability (one-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001, ns, not significant).

ABI1-TSV-11 overexpression has no influence on the proliferation of LoVo and SW480 cell lines in vitro

To test the role of ABI1-TSV-11 in LoVo and SW480 proliferation, we conducted Cell Counting Kit-8 viability assays. As shown in Fig. S4a and S4b, the viability of LoVo-ABI1-TSV-11 and SW480-ABI1-TSV-11 cell lines did not differ significantly at each time point (0, 24, and 48 h) compared with that of their corresponding controls (P > 0.05 at each time point). Therefore, ABI1-TSV-11 overexpression had no influence on the proliferation of LoVo and SW480 cell lines.

ABI1-TSV-11 enhances lung metastasis of LoVo and SW480 cells in vivo

To further verify that ABI1-TSV-11 promotes LoVo and SW480 cell migration and invasion in vivo, we established lung metastasis models by intravenously injecting LoVo-ABI1-TSV-11, LoVo-EV, SW480-ABI1-TSV-11, and SW480-EV cells into the caudal veins of immunodeficient nude mice. As shown in Fig. 5a,b, the lung metastatic lesions of mice injected with LoVo-ABI1-TSV-11 and SW480-ABI1-TSV-11 cells were more severe than those injected with LoVo-EV and SW480-EV cells, respectively. In addition, the quantitative analysis showed that average proportions of lung metastatic area of the LoVo-ABI1-TSV-11 group and SW480-ABI1-TSV-11 group were 14.7% and 7.7%, while those in the LoVo-EV group and SW480-EV group were 2.8% and 2.4%. There were significant differences in this regard between LoVo-ABI1-TSV-11 and LoVo-EV, and between SW480-ABI1-TSV-11 and SW480-EV (both P < 0.05, Fig. 5c,d).

Figure 5.

Figure 5

Open in a new tab

ABI1-TSV-11 overexpression promotes lung metastasis of LoVo and SW480 cells in vivo. (a) Lung HE staining images of LoVo-EV and LoVo-ABI1-TSV-11 cells. (b) Lung HE staining images of SW480-EV and SW480-ABI1-TSV-11 cells. (c,d) Quantitative analysis of lung metastatic area between EV groups and ABI1-TSV-11 overexpression groups. Arrows indicate the metastatic foci (t-test. *P < 0.05, **P < 0.01, ***P < 0.001, ns, not significant).

ABI1-isoform-11 affects actin dynamics of LoVo and SW480 cells by interacting with EPS8

As shown in Fig. S5 and S5b, to determine how ABI1-TSV-11 promotes LsCC metastasis, we firstly proved its overexpression did not alter WAVE2, PI3K, EPS8, and N-WASP proteins levels, and ABI1-isoform-11 could only interact with EPS8, but not with WAVE2, PI3K and N-WASP in both LoVo-ABI1-TSV-11 and SW480-ABI1-TSV-11 cells. Moreover, cellular immunofluorescence analysis proved that ABI1-isoform-11 colocalized with EPS8 at the subcellular level in LoVo-ABI1-TSV-11 and SW480-ABI1-TSV-11 cells (Fig. 7a,b), which was direct evidence of the interaction between them. Meanwhile, we also observed the co-localization of ABI1-isoform-11 and F-actin (Fig. 7a,b). Taken together, the above results indicate that the interaction of ABI1-isoform-11, ESP8, and F-actin may be the mechanism by which ABI1-TSV-11 overexpression promoted the migration and invasion of LoVo-ABI1-TSV-11 and SW480-ABI1-TSV-11 cells.

Figure 7.

Figure 7

Open in a new tab

ABI-isoform-11 co-localizes with EPS8 and F-actin in LoVo-ABI1-TSV-11 and SW480-ABI1-TSV-11 cells at the subcellular level. (a) The co-localization of ABI1-isoform-11 with EPS8 and F-actin in LoVo-ABI1-TSV-11 cells. (b) The co-localization of ABI1-isoform-11 with EPS8 and F-actin in SW480-ABI1-TSV-11 cells (blue: DAPI; green: ABI1-TSV-11; red: EPS8 or F-actin; orange: merge). Yellow arrows indicate co-localization sites.

To illustrate the relationship among ABI1-isoform-11, ESP8, and actin dynamics, we examined cell morphology, protrusions, and the co-localization of ABI1-isoform-11, EPS8, and F-actin when stimulated with PBS, fibronectin, and gelatin, respectively. We found that LoVo-ABI1-TSV-11 and SW480-ABI1-TSV-11 cells showed more protrusions and extensions when stimulated with fibronectin (Fig. 8b,e), while showing a round morphology and fewer protrusions when stimulated with PBS and gelatin (Fig. 8a,c,d,f). Moreover, the co-localization of ABI1-isoform-11, EPS8, and F-actin was mainly distributed on lamellipodium-like cellular protrusions and the direction of cell extension when simulated with fibronectin (Fig. 8b,e), while being mainly located at the position of cell–cell adhesion when stimulated with PBS and gelatin (Fig. 8a,c,d,f). Thus, we concluded that the interaction between ABI1-isoform-11 and EPS8 was consistent with actin dynamics in LoVo and SW480 cells. Finally, we analyzed the difference in co-localization of ABI1-isoform-11, EPS8, and F-actin in LoVo-ABI1-TSV-11 and SW480-ABI1-TSV-11 cells when stimulated with fibronectin. As shown in Fig. 8b,e, the co-localization of signals between ABI1-isoform-11 and F-actin was weaker and the co-localization between ABI1-isoform-11 and EPS8 was only in a limited punctate pattern in SW480-ABI1-TSV-11 cells compared with that in LoVo-ABI1-TSV-11 cells.

Figure 8.

Figure 8

Open in a new tab

The co-localization of ABI1-isoform-11 with EPS8 and F-actin in LoVo-ABI1-TSV-11 and SW480-ABI1-TSV-11 cells under different coating conditions. (a–c) The co-localization of ABI1-isoform-11 with EPS8 and F-actin in LoVo-ABI1-TSV-11 cells when coated with PBS, Fibronectin and Gelatin. (d–f) The co-localization of ABI1-isoform-11 with EPS8 and F-actin in SW480-ABI1-TSV-11 cells when coated with PBS, Fibronectin and Gelatin. (Blue: DAPI; green: ABI1-TSV-11; red: EPS8 or F-actin; orange: merge). Yellow arrows indicate co-localization sites.

Knockdown of EPS8 in ABI1-TSV-11-expressing LoVo or SW480 cells blocks cell migration and invasion, affect ABI1-TSV-11-induced cell morphology, protrusions, and the co-localization of ABI1-isoform-1 with F-actin

As shown in Fig. S1, EPS8 Knockdown models of LoVo and SW480 (with over-expressed ABI1-TSV-11) cells were successfully constructed and then migration and invasion assays were performed. We found the EPS8 Knockdown attenuates the migration of LoVo-ABI1-TSV-11 (Fig. S9) and SW480-ABI1-TSV-11 cells but not the invasion (Fig. S10) of them. We also found that EPS8 Knockdown did not change the mRNA expression of MMP2 and MMP9 (Fig. S11). As shown in Fig. S12, the knockdown of EPS8 in ABI1-TSV-11-expressing LoVo or SW480 cells do affect ABI1-TSV-11-induced protrusions, and the co-localization of ABI1-isoform-11 with F-actin but not cell morphology. EPS8 knockdown in ABI1-TSV-11-expressing LoVo or SW480 cells can cause ABI1-TSV-11 not to co-locate with F-actin well (arrow indicated).

Discussion

Although clinical and experimental studies have shown that ABI1 plays an oncogenic role in CRC, high expression or low/high phosphorylation can induce the formation of lamellar pseudopodia and the degradation of extracellular matrix in CRC cells, thus promoting the clinical metastasis of CRC8,25–27,38, these studies have not included the roles of ABI1-TSVs.To date, research on the role of ABI1 in CRC has mainly focused on the establishment of clinical correlations and the analysis of cell phenotypes in vitro, and had no evidence of animal phenotypes in vivo8,25–27,38. Most of clinical studies used immunohistochemistry and western blotting, but the existing commercial antibodies could not specifically distinguish the isoforms encoded by the ABI1-TSVs. In vitro cytology-based studies have been unable to achieve specific analysis of one or several ABI1-TSVs, so the existing studies could not fully elucidate the molecular mechanism by which ABI1 promotes CRC metastasis, and the application of early diagnosis, prognostic evaluation, and targeted intervention for CRC based on ABI1 is also greatly limited.

RNA sequencing is the current gold standard for qualitative and quantitative analyses of transcription variants46. In this study, we identified for the first time that elevated expression of ABI1-TSV-11 was related to LsCC lymph node metastasis and shorter OS, and it functions as an independent risk factor of poor prognosis in LsCC. This is consistent with the conclusion in previous studies that ABI1 acts as an oncogene in CRC8,25–27. KRAS mutation functions as an important marker of CRC metastasis47. Our study found that the expression level of ABI1-TSV-11 has no correlation with KRAS mutation, which is consistent with the conclusion reached by Sebesty’en et al.48. It may be suggested that the effect of ABI1-TSV-11 on the metastasis of LsCC is independent of KRAS mutation. On the other hand, because the sample size available in TCGA database is relatively small (55 cases), our analysis cannot exclude the correlation between ABI1-TSV-11 and KRAS. In addition, we need to further explore the role of ABI1-TSV-11 in the cells carrying wild-type KRAS outside LoVo and SW480 cell lines49.

Here, we proved that ABI1-TSV-11 overexpression does not affect the proliferation ability of LoVo and SW480 cells. It has been shown that the effect of ABI1 on cell proliferation is mainly achieved through the formation of a protein complex with PI3K (p85 subunit) and activation of the PI3K pathway17. As Fig. 6 shows, ABI1-isoform-11 lacks HHR and PxxP proline-rich domain, it cannot structurally combine with the p85 subunit of PI3K, resulting in the failure to activate LoVo and SW480 cell-related proliferation signal pathways.

Figure 6.

Figure 6

Open in a new tab

Schematic comparison of the exons and functional domains of ABI1-TSV-11 and the full-length ABI1 (ABI1-TSV-1/isoform a). (a) ABI1-TSV-11 has conserved WAVE2-binding and SH3 domains, but lacks the homeo-domain homologous region (HHR) and a majority of the PxxP- and Pro-rich domain. E: exon, pY213/421/435/506: phosphorylation at tyrosine 213/421/435/506, pSer216: phosphorylation at serine 216. WAVE-BD: WASP family verprolin-homologous protein-binding domain, HHR: homeodomain homologous region, Abl-SH3-SH2: Abl-Src homology 3-Src homology 2, Ser-rich: Serine-rich, SH3: Src homology 3.

Modified from Dubielecka et al.21.

Cell adhesion mainly occurs in the forms of cell–extracellular matrix and cell–cell adhesion, and a change of cell adhesion is necessary for tumor cells to obtain the ability to metastasize50. Change of the adhesion to fibronectin can also directly affect the movement of various tumor cells51,52. Recently, Steinestel also proved that ABI1-Y435 site phosphorylation can promote the adhesion of CRC cell CDH1 to fibronectin8. Our study found that the overexpression of ABI1-TSV-11 can significantly increase the adhesion of SW480 cells to fibronectin and inhibit the adhesion of LoVo cells to fibronectin, but compared with PBS and 0.02% BSA, the overexpression of ABI1-TSV-11 can improve the adhesion of SW480 and LoVo cells to fibronectin. That is to say, the integrated effect of ABI1-TSV-11 overexpression is still to enhance the adhesion of SW480 and LoVo cells. It makes it easier to obtain the traction that drives cell movement, and facilitates retention and implantation in the lung.

Migration and invasion represent the key cell biological events of tumor cell metastasis3. The increase and/or phosphorylation of ABI1 can promote the migration and invasion of leukemia cells9,53, breast cancer cells10,29, ovarian cancer cells11 and liver cancer cells12. In CRC, the knockdown of ABI1 significantly reduced the degradation of extracellular matrix in CRC CHD1 cells, while ABI1 Y435-phosphorylation promoted the formation of lamellar pseudopodia and the invasion of extracellular matrix in CRC cells8. Here, we found that, although ABI1-TSV-11 can enhance the migration ability of LoVo and SW480 cells, it can only enhance the invasiveness of LoVo cells without affecting that of SW480 cells (as shown in Fig. 4). LoVo cells originated from metastasis of the upper left clavicle, with high malignancy, strong metastasis, and strong invasion54,55, while SW480 cells originated from a primary tumor of rectal adenocarcinoma, with low malignancy and metastatic potential56. The difference in the way in which ABI1-TSV-11 overexpression affected the invasiveness of LoVo and SW480 cells also confirms the results obtained in our previous clinical studies, further indicating that ABI1-TSV-11 could be an important candidate target for the treatment of LsCC metastasis.

To date, in vivo study on the role of ABI1 in tumor metastasis has been mainly related to the study of leukemia, breast cancer, and liver cancer9,10,12,57, but there are no related reports on CRC. Here, we chose a lung metastasis model of nude mice to evaluate the effect of ABI1-TSV-11 on the metastasis of CRC cells in vivo. The results showed that ABI1-TSV-11 overexpression promoted the process of lung metastasis of LoVo and SW480 cells in vivo, which was consistent with the results of in vitro experiments, and further proved that the overexpression of ABI1-TSV-11 enhanced the metastatic ability of LoVo and SW480 cells.

ABI1 can regulate actin aggregation and cytoskeleton reconstruction by forming complexes with WAVE2, PI3K, EPS8, and/or N-WASP17,20,23,24, and thus play an important role in the metastasis of various malignant tumors including CRC8–12,27,29,37. Now we proved that ABI1-isoform-11 interacted only with EPS8 in LoVo and SW480 cells (as shown in Figs. 7, 8), and the co-localization of ABI1-isoform-11 and EPS8 were consistent with the dynamic change of F-actin, specifically with the related trend of lamellar pseudopodium formation and cell extension. Actin dynamics and cytoskeleton changes are the basis of tumor cell adhesion, migration, and invasion58,59. The binding of ABI1 and EPS8 could not only affect the localization and/or activity of actin nucleation, regulate the reconstruction of the actin cytoskeleton, and promote the assembly of filopodium structure and actin filaments of human breast cancer cells and mouse melanoma cells22, also seal the hook end of EPS8, promote actin capping, and directly induce F-actin-rich structure formation60. As shown in Fig. S12, the knockdown of EPS8 in ABI1-TSV-11-expressing LoVo or SW480 cells do affect ABI1-TSV-11-induced protrusions, and the co-localization of ABI1-isoform-11 with F-actin but not cell morphology. Taken these findings together, we believe that ABI1-isform-11 can regulate actin dynamics and cytoskeleton remodeling by interacting with EPS8, thus promoting the adhesion and migration of LoVo and SW480 cells in vitro and accelerating the process of lung metastasis in vivo. However, TCGA database shows that multiple ABI1 TSVs are often expressed in CRC at the same time, and there are potential synergistic or antagonistic effects among different TSVs. Therefore, it is necessary to integrate them with changes in expression, abnormal phosphorylation, and differences in complex formation to systematically elucidate the exact molecular mechanism of ABI1 in CRC metastasis.

In summary, we believe that ABI1-TSV-11 is a specific prognostic factor and therapy target for LsCC, and the current results of this study open up a new field for us to use TSV-specific nucleic acid detection technology61 and ASO (antisense oligonucleotide) target technology62 for the diagnostic classification, prognostic evaluation, and targeted treatment of CRC metastasis.

Material and methods

Acquisition and grouping of clinicopathological information and mRNA sequencing data

We downloaded clinicopathological information of 634 CRC patients from TCGA (version 20,160,128), and ABI1 TSV sequencing data of 382 CRC patients from TSVdb. 339 CRC adenocarcinoma patients with complete survival data were selected into our study, and then divided LsCC (n = 168) and RsCC (n = 154) subgroups according to the primary tumor sites (unknown = 17).

Cell lines and cell culture

SW480, SW620, LoVo and CRL-1541 cell lines were purchased from the Chinese Academy of Science (Shanghai, China) and ATCC, and cultured in DMEM supplemented with 10% FBS and 1% penicillin & streptomycin.

Construction of stable and transient cell lines

To establish stable ABI1-TSV-11-overexpressing cell lines, LoVo and SW480 cells were infected with lentivirus at a multiplicity of infection of 30 in the presence of 7 μg/ml polybrene. After puromycin selection for 2 weeks, the expression level of ABI1-TSV-11 was determined by quantitative real-time PCR (qRT-PCR) and western blotting using HA-tag antibody (#3724; CST, MA, USA). To knockdown EPS8 transiently in ABI1-TSV-11-overexpressing cell lines, EPS8 and Non-targeting Control (NC) siRNAs (5’-TCGGTTCTAAAGGATGATATT-3’ and 5’-UUCUCCGAACGUGUCACGUdTdT-3’, respectively) were transfected with lipofectamine 3000. After 48 h, the expression level of EPS8 was determined by qRT-PCR.

qRT-PCR

qRT-PCR was performed as previously described9. The primers were listed in Supplement Materials (Table S1) and the amplification was conducted and analyzed by CFX96 (Bio-Rad, Hercules, CA, USA).

Integrins mRNA expression profile of LoVo and SW480 cells

RNA sequencing was performed using the Illumina HiSeq 2000 RNA Sequencing platform ((MGI, Shenzhen, P. R. China)) and the integrins mRNA expression profile of LoVo and SW480 cells was constructed with normalized FPKM count.

Proliferation, adhesion, migration, and invasion analyses of cells in vitro

Cell proliferation assays were performed using Cell Counting Kit-8 (CK04-100, CCK8; Dojindo, Rockville, MD, USA). Adhesion assays were conducted with 24-well plates (3524; Corning) coated with different materials, namely, PBS, (21–040-CV; Corning), 0.2% BSA (A-1933; Sigma), fibronectin (5 μg/ml) (F1141; Sigma), collagen I (C9879; Sigma), and 0.1% gelatin (ES-006-B; Millipore, MA, USA). Migration and invasion assays were performed with a 24-well Transwell chamber with 8.0-μm-pore polycarbonate filter inserts (3422; Corning). We seeded cells on the upper chambers without or with Matrigel (356,234; Corning, 300 μg/ml). We counted the cells that had migrated to the lower side of the insert membrane at 4 h (LoVo-ABI1-TSV-11 and parental cells; LoVo-ABI1-TSV-11-EPS-siRNA and LoVo-ABI1-TSV-11-NC-siRNA) or 8 h (SW480-ABI1-TSV-11 and parental cells; SW480-ABI1-TSV-11-EPS-siRNA and SW480-ABI1-TSV-11-NC-siRNA) after seeding cells, and counted the cells that had invaded to the lower side of the insert membrane at 8 h (LoVo-ABI1-TSV-11 and parental cells; LoVo-ABI1-TSV-11-EPS-siRNA and LoVo-ABI1-TSV-11-NC-siRNA) and 14 h (LoVo-ABI1-TSV-11 and parental cells;SW480-ABI1-TSV-11-EPS-siRNA and SW480-ABI1-TSV-11-NC-siRNA) after seeding.

Establishment of colorectal cancer lung metastasis model

All animal care and handling procedures were were approved by the Ethics Committee of Peking University People’s Hospital BALB/c nude mice (6–8 weeks old; Charles River, Beijing, China) were kept in SPF conditions and randomly assigned into four groups (six mice per group). LoVo-ABI1-TSV-11, LoVo-EV, SW480-ABI1-TSV-11, and SW480-EV (each 1 × 106) cells were injected into the tail veins of nude mice. At 16 weeks after injection, all tested mice were sacrificed with the signs of cachexia appearing, and qualitative and quantitative analyses of lung metastases were conducted by hematoxylin and eosin (H&E) staining, Nano-Zoomer Digital Pathology S360 (Hamamatsu Photonics, Shizuoka, Japan), and ImageJ (National Institutes of Health, USA).

Western blotting and co-immunoprecipitation

Western blot and immunoprecipitation analysis were performed as previously described9. The antibodies were listed in Supplement Materials (Table S2).

Immunofluorescence

LoVo-ABI1-TSV-11 and SW480-ABI1-TSV-11, LoVo-ABI1-TSV-11-EPS-siRNA and LoVo-ABI1-TSV-11-NC-siRNA, SW480-ABI1-TSV-11-EPS-siRNA and SW480-ABI1-TSV-11-NC-siRNA cell lines were cultured on chambers (154,526; Thermo Fisher Scientific, MA, USA). The cells were fixed in 4% paraformaldehyde in PBS for 10 min and permeabilized with 0.2% Triton X-100 in PBS for 5 min. Nonspecific binding was blocked by incubation with normal goat serum. Then cells were incubated with the primary antibody EPS8 or Phalloidin-iFluor-647 working solution. After washing with PBS, cells were incubated with TRITC-Labeled Goat Anti-Rabbit IgG (skip this step when staining F-actin), followed by counterstaining with DAPI. The images were acquired by confocal laser scanning microscopy (CLSM, TCS-SP8/STED 3X; Leica, Germany). The information of antibodies and dyes were listed in Supplement Materials (Table S2).

Statistical analysis

Statistical analysis and graph drawing were performed using SPSS 20.0 (IBM, Chicago, IL, USA) and GraphPad Prism 8.0 (La Jolla, CA, USA). X-tile 3.6.1 (Yale University School of Medicine, New Haven, CT, USA) was used to confirm the most suitable cut-off points to define low and high ABI1-TSV-11 expression. Chi-square test was used to compared two groups, and one-way ANOVA was used to compare three or more groups. Kaplan–Meier analysis and log-rank test were used to survival analysis. The Cox proportional hazards regression model was used to univariate and multivariate analysis to determine the effect of ABI1-TSV-11 on OS. P-values < 0.05 were considered to be statistic significant. All p-values correspond to two-sided significance tests.

Approval for animal experiments

The animal experiments were approved by the Ethics Committee of Peking University People’s Hospital and all animal care and handling procedures were performed according to the National Institutes of Health's Guide for the Care and Use of Laboratory Animals. The study was carried out in compliance with the ARRIVE guidelines 2.0 (https://arriveguidelines.org).

Supplementary Information

Supplementary Figures and Tables. (1.5MB, pdf)

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (Nos. 30872923, 81672853, 31500098) and Peking University People’s Hospital Research and Development Foundation (No. RDB 2020-11). We also thank the editors from BioMed Proofreading LLC for comprehensive editing of this manuscript.

Author contributions

W.D.Y. and J.Z.G. designed the study; Y.Z. and Z.H.Z. conducted the experiments, analyzed the data and wrote the paper; M.L., J.Y.C., T.R.L., J.S., D.W., Q.M., H.T.S., N.W., A.Y.L., Y.M.Y. performed part of the protein-related experiments; M.L.Z. performed part of animal experiments; Y.L.L. supervised the study. All authors reviewed the manuscript.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Yu Zhang and Zhaohui Zhong.

Contributor Information

Jingzhu Guo, Email: guojingzhu@pkuph.edu.cn.

Weidong Yu, Email: weidongyu@bjmu.edu.cn.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-021-90220-8.

References

  • 1.Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. [DOI] [PubMed] [Google Scholar]
  • 2.Christofori G. New signals from the invasive front. Nature. 2006;441:444–450. doi: 10.1038/nature04872. [DOI] [PubMed] [Google Scholar]
  • 3.Christine LC, Robert AW. A perspective on cancer cell metastasis. Science. 2011;331:1559–1564. doi: 10.1126/science.1203543. [DOI] [PubMed] [Google Scholar]
  • 4.Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275–292. doi: 10.1016/j.cell.2011.09.024. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat. Med. 2006;12:895–904. doi: 10.1038/nm1469. [DOI] [PubMed] [Google Scholar]
  • 6.Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur. J. Cancer. 2017;84:69–80. doi: 10.1016/j.ejca.2017.07.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Shen H, et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J. Gastroenterol. 2015;21:6470–6478. doi: 10.3748/wjg.v21.i21.6470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Steinestel K, et al. Expression and Y435-phosphorylation of Abelson interactor 1 (Abi1) promotes tumour cell adhesion, extracellular matrix degradation and invasion by colorectal carcinoma cells. Mol. Cancer. 2014;13:145. doi: 10.1186/1476-4598-13-145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Yu WD, Sun XL, Clough N, Everardo C, Tao YX, Dai ZH. Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo. Carcinogenesis. 2008;29:1717–1724. doi: 10.1093/carcin/bgn098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Sun X, et al. Abl interactor 1 regulates Src-Id1-matrix metalloproteinase 9 axis and is required for invadopodia formation, extracellular matrix degradation and tumor growth of human breast cancer cells. Carcinogenesis. 2009;30:2109–2116. doi: 10.1093/carcin/bgp251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Chen H, Wu X, Pan ZK, Huang S. Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis. Cancer Res. 2010;70:9979–9990. doi: 10.1158/0008-5472.CAN-10-2394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Wang JL, Yan TT, Long C, Cai WW. Oncogenic function and prognostic significance of Abelson interactor 1 in hepatocellular carcinoma. Int. J. Oncol. 2017;50:1889–1898. doi: 10.3892/ijo.2017.3920. [DOI] [PubMed] [Google Scholar]
  • 13.Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat. Rev. Cancer. 2005;5:172–183. doi: 10.1038/nrc1567. [DOI] [PubMed] [Google Scholar]
  • 14.Shi YG, Alin K, Stephen PG. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity. Genes Dev. 1995;9:2583–2597. doi: 10.1101/gad.9.21.2583. [DOI] [PubMed] [Google Scholar]
  • 15.Wang BL, Erica AG, Gary DK. ArgBP2, a multiple Src homology 3 domain-containing, Arg:Abl-interacting protein, is phosphorylated in v-Abl-transformed cells and localized in stress fibers and cardiocyte Z-disks*. J. Biol. Chem. 1997;272:17542–17550. doi: 10.1074/jbc.272.28.17542. [DOI] [PubMed] [Google Scholar]
  • 16.Biesova Z, Piccoli C, Wong WT. Isolation and characterization of e3B1, an eps8 binding protein that regulates cell growth. Oncogene. 1997;14:233–241. doi: 10.1038/sj.onc.1200822. [DOI] [PubMed] [Google Scholar]
  • 17.Innocenti M, et al. Phosphoinositide 3-kinase activates Rac by entering in a complex with Eps8, Abi1, and Sos-1. J. Cell Biol. 2003;160:17–23. doi: 10.1083/jcb.200206079. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Xiong X, et al. Disruption of Abi1/Hssh3bp1 expression induces prostatic intraepithelial neoplasia in the conditional Abi1/Hssh3bp1 KO mice. Oncogenesis. 2012;1:e26. doi: 10.1038/oncsis.2012.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ryu JR, Echarri A, Li R, Pendergast AM. Regulation of cell–cell adhesion by Abi/Diaphanous complexes. Mol. Cell. Biol. 2009;29:1735–1748. doi: 10.1128/MCB.01483-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Innocenti M, et al. Abi1 is essential for the formation and activation of a WAVE2 signalling complex. Nat. Cell. Biol. 2004;6:319–327. doi: 10.1038/ncb1105. [DOI] [PubMed] [Google Scholar]
  • 21.Dubielecka PM, et al. Differential regulation of macropinocytosis by Abi1/Hssh3bp1 isoforms. PLoS ONE. 2010;5:e10430. doi: 10.1371/journal.pone.0010430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Roffers-Agarwal J, Xanthos JB, Miller JR. Regulation of actin cytoskeleton architecture by Eps8 and Abi1. BMC Cell Biol. 2005;6:36. doi: 10.1186/1471-2121-6-36. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Giorgio S, et al. EPS8 and E3B1 transduce signals from Ras to Rac. Nature. 1999;401:1327–1340. doi: 10.1038/45822. [DOI] [PubMed] [Google Scholar]
  • 24.Innocenti M, et al. Abi1 regulates the activity of N-WASP and WAVE in distinct actin-based processes. Nat. Cell Biol. 2005;7:969–976. doi: 10.1038/ncb1304. [DOI] [PubMed] [Google Scholar]
  • 25.Li K, Li M, Liu YL, Ma SY, Yu WD. The relationshaip between ABI1 upregulation and the clinicopathologic features and prognosis of colon adenocarcinoma. Chin. J. Gen. Surg. 2015;30:643–646. doi: 10.3760/cma.j.issn.1007-631X.2015.08.017. [DOI] [Google Scholar]
  • 26.Steinestel K, et al. Expression of Abelson interactor 1 (Abi1) correlates with inflammation, KRAS mutation and adenomatous change during colonic carcinogenesis. PLoS ONE. 2012;7:e40671. doi: 10.1371/journal.pone.0040671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Steinestel K, et al. Abelson interactor 1 (Abi1) in colorectal cancer. From synaptic plasticity to tumor cell migration. Pathologe. 2013;34(Suppl 2):189–194. doi: 10.1007/s00292-013-1810-1. [DOI] [PubMed] [Google Scholar]
  • 28.Li YZ, et al. BCR-ABL induces abnormal cytoskeleton remodeling, β1 integrin clustering, and increased cell adhesion to fibronectin through ABL interactor 1 pathway. J. Cell. Sci. 2007;120:1436–1446. doi: 10.1242/jcs.03430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wang C, et al. Abelson interactor protein-1 positively regulates breast cancer cell proliferation, migration, and invasion. Mol. Cancer Res. 2007;5:1031–1039. doi: 10.1158/1541-7786.MCR-06-0391. [DOI] [PubMed] [Google Scholar]
  • 30.Wang C, et al. Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation. Breast Cancer Res. Treat. 2010;129:373–386. doi: 10.1007/s10549-010-1241-0. [DOI] [PubMed] [Google Scholar]
  • 31.Zhang J, et al. Upregulation of Abelson interactor protein 1 predicts tumor progression and poor outcome in epithelial ovarian cancer. Hum. Pathol. 2015;46:1331–1340. doi: 10.1016/j.humpath.2015.05.015. [DOI] [PubMed] [Google Scholar]
  • 32.Liu SY, Wu F, Tao YM, Yang LY. Increased expression of Abi1 in hepatocellular carcinoma and its correlation with poor prognosis of hepatocellular carcinoma. Zhonghua Wai Ke Za Zhi. 2009;47:1732–1735. doi: 10.3760/cma.j.issn.0529-5815.2009.22.015. [DOI] [PubMed] [Google Scholar]
  • 33.Nath D, et al. Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling. Cell Commun. Signal. 2019;17:120. doi: 10.1186/s12964-019-0410-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Macoska JA, et al. Loss of expression of human spectrin Src homology domain binding protein 1 is associated with 10p loss in human prostatic adenocarcinoma1. Neoplasia. 2001;3:90–104. doi: 10.1038/sj.neo.7900145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Cui MH, Yu WD, Dong JQ, Chen J, Zhang XR, Liu YL. Downregulation of ABI1 expression affects the progression and prognosis of human gastric carcinoma. Med. Oncol. 2010;27:632–639. doi: 10.1007/s12032-009-9260-6. [DOI] [PubMed] [Google Scholar]
  • 36.Cui MH, Yu W, Dong JQ, Liu YL. Overexpression of Abl interactor 1 affects proliferation of gastric cancer cell line AGS Natl. Med. J. China. 2009;89:3111–3115. doi: 10.3760/ema.j.isstr. [DOI] [PubMed] [Google Scholar]
  • 37.Liu X, et al. MiR-181a/b induce the growth, invasion, and metastasis of neuroblastoma cells through targeting ABI1. Mol. Carcinog. 2018;57:1237–1250. doi: 10.1002/mc.22839. [DOI] [PubMed] [Google Scholar]
  • 38.Baba RA, et al. E3B1/ABI-1 isoforms are down-regulated in cancers of human gastrointestinal tract. Dis. Markers. 2012;32:273–279. doi: 10.3233/DMA-2011-0881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 2008;40:1413–1415. doi: 10.1038/ng.259. [DOI] [PubMed] [Google Scholar]
  • 40.Bisognin A, et al. An integrative framework identifies alternative splicing events in colorectal cancer development. Mol. Oncol. 2014;8:129–141. doi: 10.1016/j.molonc.2013.10.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Huerta S, et al. Alternative mRNA splicing in colon cancer causes loss of expression of neural cell adhesion molecule. Surgery. 2001;130:834–843. doi: 10.1067/msy.2001.116415. [DOI] [PubMed] [Google Scholar]
  • 42.https://www.ncbi.nlm.nih.gov/gene/10006.
  • 43.Alexandra I, Yang HY, Gao GX, Stephen PG. Inhibition of v-Abl transformation in 3T3 cells overexpressing different forms of the Abelson interactor protein Abi-1. Oncogene. 2001;20:4926–4934. doi: 10.1038/sj.onc.1204502. [DOI] [PubMed] [Google Scholar]
  • 44.Tomczak K, Czerwinska P, Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp. Oncol. (Pozn.) 2015;19:A68–77. doi: 10.5114/wo.2014.47136. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Sun W, et al. TSVdb: a web-tool for TCGA splicing variants analysis. BMC Genomics. 2018;19:405. doi: 10.1186/s12864-018-4775-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Kyrochristos ID, Ziogas DE, Goussia A, Glantzounis GK, Roukos DH. Bulk and single-cell next-generation sequencing: individualizing treatment for colorectal cancer. Cancers (Basel) 2019 doi: 10.3390/cancers11111809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Boutin AT, et al. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev. 2017;31:370–382. doi: 10.1101/gad.293449.116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Sebestyen E, Zawisza M, Eyras E. Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer. Nucleic Acids Res. 2015;43:1345–1356. doi: 10.1093/nar/gku1392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Haliassos A, et al. Detection of minority point mutations by modified PCR technique: a new approach for a sensitive diagnosis of tumor-progression markers. Nucleic Acids Res. 1989;17:8093–8099. doi: 10.1093/nar/17.20.8093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Suresh S. Biomechanics and biophysics of cancer cells. Acta Biomater. 2007;3:413–438. doi: 10.1016/j.actbio.2007.04.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Singh J, Hussain F, Decuzzi P. Role of differential adhesion in cell cluster evolution: from vasculogenesis to cancer metastasis. Comput. Methods Biomech. Biomed. Eng. 2015;18:282–292. doi: 10.1080/10255842.2013.792917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Wirtz D, Konstantopoulos K, Searson PC. The physics of cancer: the role of physical interactions and mechanical forces in metastasis. Nat. Rev. Cancer. 2011;11:512–522. doi: 10.1038/nrc3080. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Sun X, et al. MT1-MMP as a downstream target of BCR-ABL/ABL interactor 1 signaling: polarized distribution and involvement in BCR-ABL-stimulated leukemic cell migration. Leukemia. 2008;22:1053–1056. doi: 10.1038/sj.leu.2404990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Drewinko B, Romsdahl MM, Yang LY, Ahearn MJ, Trujlilo JM. Establishment of a human carcinoembryonic antigen-producing colon adenocarcinoma cell line. Cancer Res. 1976;36:467–475. [PubMed] [Google Scholar]
  • 55.Drewinko B, et al. Further biologic characteristics of a human carcinoembryonic antigen-producing colon carcinoma cell line. J. Natl. Cancer Inst. 1978 doi: 10.1093/jnci/61.1.75. [DOI] [PubMed] [Google Scholar]
  • 56.Andreas PK, et al. Growth patterns and metastatic behavior of human tumors growing in athymic mice. Cancer Res. 1978;38:3186–3190. [PubMed] [Google Scholar]
  • 57.Faulkner J, Jiang P, Farris D, Walker R, Dai Z. CRISPR/CAS9-mediated knockout of Abi1 inhibits p185(Bcr-Abl)-induced leukemogenesis and signal transduction to ERK and PI3K/Akt pathways. J. Hematol. Oncol. 2020;13:34. doi: 10.1186/s13045-020-00867-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Fife CM, McCarroll JA, Kavallaris M. Movers and shakers: cell cytoskeleton in cancer metastasis. Br. J. Pharmacol. 2014;171:5507–5523. doi: 10.1111/bph.12704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin. Exp. Metastasis. 2009;26:273–287. doi: 10.1007/s10585-008-9174-2. [DOI] [PubMed] [Google Scholar]
  • 60.Disanza A, et al. Eps8 controls actin-based motility by capping the barbed ends of actin filaments. Nat. Cell Biol. 2004;6:1180–1188. doi: 10.1038/ncb1199. [DOI] [PubMed] [Google Scholar]
  • 61.Ren X, et al. SpliceRCA: in situ single-cell analysis of mRNA splicing variants. ACS Cent. Sci. 2018;4:680–687. doi: 10.1021/acscentsci.8b00081. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Bennett CF. Therapeutic antisense oligonucleotides are coming of age. Annu. Rev. Med. 2019;70:307–321. doi: 10.1146/annurev-med. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Figures and Tables. (1.5MB, pdf)

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES